Anthracycline cardiotoxicity: an update on mechanisms, monitoring and prevention

PA Henriksen - Heart, 2018 - heart.bmj.com
Anthracycline chemotherapy causes dose-related cardiomyocyte injury and death leading to
left ventricular dysfunction. Clinical heart failure may ensue in up to 5% of high-risk patients …

Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: a systematic review

P Thavendiranathan, F Poulin, KD Lim, JC Plana… - Journal of the American …, 2014 - jacc.org
The literature exploring the utility of advanced echocardiographic techniques (such as
deformation imaging) in the diagnosis and prognostication of patients receiving potentially …

[HTML][HTML] Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations

G Curigliano, D Lenihan, M Fradley, S Ganatra… - Annals of …, 2020 - Elsevier
Cancer and cardiovascular (CV) disease are the most prevalent diseases in the developed
world. Evidence increasingly shows that these conditions are interlinked through common …

Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab

H Sawaya, IA Sebag, JC Plana, JL Januzzi… - Circulation …, 2012 - Am Heart Assoc
Background—Because cancer patients survive longer, the impact of cardiotoxicity
associated with the use of cancer treatments escalates. The present study investigates …

Expert consensus for multi-modality imaging evaluation of cardiovascular complications of radiotherapy in adults: a report from the European Association of …

P Lancellotti, VT Nkomo, LP Badano… - European Heart …, 2013 - academic.oup.com
Cardiac toxicity is one of the most concerning side effects of anti-cancer therapy. The gain in
life expectancy obtained with anti-cancer therapy can be compromised by increased …

Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and …

JC Plana, M Galderisi, A Barac, MS Ewer… - European Heart …, 2014 - academic.oup.com
Cardiac dysfunction resulting from exposure to cancer therapeutics was first recognized in
the 1960s, with the widespread introduction of anthracyclines into the oncological …

Early detection and prediction of cardiotoxicity in chemotherapy-treated patients

H Sawaya, IA Sebag, JC Plana, JL Januzzi, B Ky… - The American journal of …, 2011 - Elsevier
As breast cancer survival increases, cardiotoxicity associated with chemotherapeutic
regimens such as anthracyclines and trastuzumab becomes a more significant issue …

Cardiac side-effects of cancer chemotherapy

JJ Monsuez, JC Charniot, N Vignat… - International journal of …, 2010 - Elsevier
The spectrum of cardiac side-effects of cancer chemotherapy has expanded with the
development of combination, adjuvant and targeted chemotherapies. Their administration in …

Comprehensive assessment of changes in left ventricular diastolic function with contemporary breast cancer therapy

JN Upshaw, B Finkelman, RA Hubbard… - JACC: Cardiovascular …, 2020 - jacc.org
Objectives: This study determined the effects of doxorubicin and/or trastuzumab on diastolic
function and the relationship between diastolic function and systolic dysfunction …

2D and 3D strain for detection of subclinical anthracycline cardiotoxicity in breast cancer patients: a balance with feasibility

C Santoro, G Arpino, R Esposito… - European Heart …, 2017 - academic.oup.com
Aims 2D echocardiography is limited for identifying chemotherapy-related cardiotoxicity.
This study compared standard echo, 2D, and 3D speckle tracking echocardiography (STE) …